Norman Fultang

Norman Fultang

Auto-generated profile, based on publicly available information

Norman Fultang

Department of Biology, University of The Sciences in Philadelphia, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NFNorman Fultang
Norman Fultang
AIAbhinav Illendula
Abhinav Illendula
JLJianhuang Lin
Jianhuang Lin
MPManoj K. Pandey
Manoj K. Pandey
ZKZachary Klase
Zachary Klase
Bela PeethambaranBela Peethambaran
Bela Peethambaran
Chemoresistance is one of the leading causes of mortality in breast cancer (BC). Understanding the molecules regulating chemoresistance is critical in order to combat chemoresistant BC. Drug efflux pump ABCB1 is overexpressed in chemoresistant neoplasms where it effluxes various chemotherapeutic agents from cells. Because it is expressed in normal and cancerous cells alike, attempts at targeting ABCB1 directly have failed due to low specificity and disruption of normal tissue. A proposed method to inhibit ABCB1 is to target its cancer-specific, upstream regulators, mitigating damage to normal tissue. Few such cancer-specific upstream regulators have been described. Here we characterize ROR1 as an upstream regulator of ABCB1. ROR1 is highly expressed during development but not expressed in normal adult tissue. It is however highly expressed in several cancers. ROR1 is overexpressed in chemoresistant BC where it correlates with poor therapy response and tumor recurrence. Our data suggests, ROR1 inhibition sensitizes BC cells to chemo drugs. We also show ROR1 regulates ABCB1 stability and transcription via MAPK/ERK and p53. Validating our overall findings, inhibition of ROR1 directly correlated with decreased efflux of chemo-drugs from cells. Overall, our results highlight ROR1’s potential as a therapeutic target for multidrug resistant malignancies.

31 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NFNorman Fultang
Norman Fultang
AIAbhinav Illendula
Abhinav Illendula
BCBrian Chen
Brian Chen
CWChun Wu
Chun Wu
SJSubash Jonnalagadda
Subash Jonnalagadda
Bela PeethambaranBela Peethambaran
Bela Peethambaran
Triple Negative Breast Cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by the absence of hormone receptors usually targeted by hormone therapies like Tamoxifen. Because therapy success and survival rates for TNBC lag far behind other breast cancer subtypes, there is significant interest in developing novel anti-TNBC agents that can target TNBC specifically, with minimal effects on non-malignant tissue. To this aim, our study describes the anti-TNBC effect of strictinin, an ellagitanin previously isolated from Myrothamnus flabellifolius. Using various in silico and molecular techniques, we characterized the mechanism of action of strictinin in TNBC. Our results suggest strictinin interacts strongly with Receptor Tyrosine Kinase Orphan like 1 (ROR1). ROR1 is an oncofetal receptor highly expressed during development but not in normal adult tissue. It is highly expressed in several human malignancies however, owing to its numerous pro-tumor functions. Via its interaction and inhibition of ROR1, strictinin reduced AKT phosphorylation on ser-473, inhibiting downstream phosphorylation and inhibition of GSK3β. The reduction in AKT phosphorylation also correlated with decreased cell survival and activation of the caspase-mediated intrinsic apoptotic cascade. Strictinin treatment also repressed cell migration and invasion in a beta-catenin independent manner, presumably via the reactivated GSK3ß’s repressing effect on microtubule polymerization and focal adhesion turnover. This could be of potential therapeutic interest considering heightened interest in ROR1 and other receptor tyrosine kinases as targets for development of anti-cancer agents. Further studies are needed to validate these findings in other ROR1-expressing malignancies but also in more systemic models of TNBC. Our findings do however underline the potential of strictinin and other ROR1-targeting agents as therapeutic tools to reduce TNBC proliferation, survival and motility.

7 July 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
AIAbhinav Illendula
Abhinav Illendula
NFNorman Fultang
Norman Fultang
Bela PeethambaranBela Peethambaran
Bela Peethambaran
Neuroblastoma is the most common inheritable, solid neoplasm in children found under the age of 7 and accounts for approximately 7% of childhood cancers. A common treatment that has been prescribed for over a decade is retinoid therapy [using all‑trans retinoic acid (RA)]. Treatment with this differentiating agent has been revealed to progress the cells from their stem‑cell state to a mature neuronal state gaining classical neuronal characteristics, including the suppression of proliferation. However, the molecular mechanism underlying the action of RA treatment remains to be elucidated. In the present study, a novel mechanism of RA‑induced differentiation via regulation of receptor tyrosine kinase‑like orphan receptor 1 (ROR1) is reported. ROR1 is overexpressed in neuroblastoma but significantly downregulated in mature differentiated neurons. Hence, it was hypothesized that RA may modulate ROR1 leading to differentiation and termination of cancerous properties. Immunoblotting revealed that following RA treatment, ROR1 levels initially increased then sharply decreased by 96 h. This was paired with synaptophysin, a mature neuron marker, sharply increasing concurrently, providing evidence of differentiation by 96 h. Investigation of the ROR1 pathway confirmed ROR1‑dependent downstream activation of the PI3K/AKT signaling axis, a growth pathway previously demonstrated to promote differentiation. Chromatin immunoprecipitation revealed an increase in RAR binding to the promoters of ROR1 and its endogenous ligand, Wnt5a. This research provided compelling evidence that RA is able to modulate the expression of ROR1 and Wnt5a to promote differentiation through the expression of synaptophysin. This data combined with the overarching data from the scientific community regarding proliferation and other proliferative factors in early‑stage neurons provides a more in‑depth model of the process of differentiation in neurons.

3 January 2018 in Journal of Medicinal Plants Research
Verified
Journal Article
Open access
PDF file
BJBrar Jaspal
Brar Jaspal
FNFultang Norman
Fultang Norman
AKAskey Kayla
Askey Kayla
CMCristina Tettamanzi Maria
Cristina Tettamanzi Maria
PBPeethambaran Bela
Peethambaran Bela
Triple negative breast cancer (TNBC) is a disease that impacts millions of people around the world. There is an urgent need to find new therapies, specific to triple negative cancer cells with minimal effect on normal cells. This study explores the use of Myrothamnus flabellifolius as an anti-TNBC. Using High Performance Liquid Chromatography, the extract was fractionated and each fraction was tested against TNBC cells BT-549 and MDA-MB-231, and a non-malignant breast cell line MCF-10A. The results showed that fraction 7 inhibited the growth of TNBC cells starting at a dry weight concentration of 31.125 μg/mL while there was no significant cell death of the MCF-10A cell line. Using analytical techniques such as Mass Spectrometry (MS-MS) and Nuclear Magnetic Resonance (NMR), the major compound in fraction 7 was determined to be a derivative of galloyl glucose hexahydroxydiphenic acid. The results suggest that this novel compound is the primary anti-TNBC compound in M. flabellifolius and might be a potential candidate for targeted TNBC therapy. Key words: Triple negative breast cancer, Myrothamnus flabellifolius, natural products, galloyl glucose hexahydroxydiphenic acid derivative.

15 February 2018 in Cancer Research
Verified
Journal Article
Closed access
NFN Fultang
N Fultang
ZKZ Klase
Z Klase
IMI Mercier
I Mercier
BPB Peethambaran
B Peethambaran
Triple negative breast cancer (TNBC) represents approximately 20% of all breast cancer cases worldwide. Prognosis for this subtype of cancer is especially dire due to the absence of Estrogen (ER), Progesterone and Human Epidermal Growth Factor receptors, usually targeted by neoadjuvant therapies like Tamoxifen. Myrothamnus flabellifolius (MF), a well-studied South African medicinal herb, has shown significant potency against TNBC with minimal effect on normal cells. In this study, we use miRNA profiling, Ingenuity Pathway Analysis (Qiagen), MTT, immunoblots and immunofluorescence to characterize the targeted cytotoxic mechanism of MF in TNBC. We found deregulation in the expression of several oncogenic and anti-cancer miRNAs in TNBC post MF treatment. Using Ingenuity Pathway Analysis to analyze the miRNA expression profiles of the treated cells, we determined Estrogen Signaling as a pathway significantly affected by MF in TNBC. Immunoblots confirmed increase of the ERa/ERß ratio in TNBC, a well-studied marker for Tamoxifen-therapy sensitivity in TNBC. MTT cell viability assay and Annexin V staining confirmed increased sensitivity to Tamoxifen post treatment with low doses of MF, with up to 70% cell death at half the IC50 of Tamoxifen in TNBC. This study establishes a potential non-toxic therapeutic to supplement Estrogen-receptor targeting therapies in TNBC by increasing the ERa/ERß ratio. The data also evaluates the ERa/ERß ratio as a potential target for combination therapies in TNBC. Citation Format: Fultang N, Klase Z, Mercier I, Peethambaran B. MicroRNA-mediated restoration of tamoxifen sensitivity in triple negative breast cancer through modulation of estrogen receptor alpha/beta ratio using Myrothamnus flabellifolius [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-07-13.

28 November 2017 in Journal of Environmental Science and Engineering - A
Verified
Journal Article
Open access
AOAnne Osano
Anne Osano
NFNorman Fultang
Norman Fultang
JDJarrett Davis
Jarrett Davis